Panacea Biotec Share Price

Please find enclosed newspaper copies of the public notice, requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.

• BSE India
• 4 days 14 hours ago

Please find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026, published on 14.08.2026.

• BSE India
• 1 week 1 day ago

<h3><span style="font-size:16px;"><strong>Biotechnology company Panacea Biotec announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Total income from operations for Q1FY27 stood at Rs 19,957 lakh, compared to Rs 16,670 lakh in Q1FY26, representing a YoY growth of 19.72%. On a QoQ basis, it increased by 19.68% from Rs 16,675 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total income for the quarter reached Rs 20,381 lakh in Q1FY27, up 18.24% YoY from Rs 17,237 lakh in Q1FY26 and up 20.38% QoQ from Rs 16,930 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Net profit for Q1FY27 was reported at Rs 220 lakh, as against a net profit of Rs 396 lakh in Q1FY26, marking a YoY decrease of 44.44%. However, the company turned profitable on a QoQ basis compared to a loss of Rs 100 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total comprehensive income for Q1FY27 was Rs 258 lakh, a decrease of 34.52% YoY from Rs 394 lakh in Q1FY26 and a decrease of 35.34% QoQ from Rs 399 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Earnings per share (Basic and Diluted) for Q1FY27 was Rs 0.38, compared to Rs 0.66 in Q1FY26 and Rs 0.08 in Q4FY26.</li> </ul> <p><strong _ngcontent-ng-c1940132427="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427="">Total income from operations for Q1FY27 was Rs 13,471 lakh, recording a YoY growth of 20.01% from Rs 11,225 lakh in Q1FY26 and a QoQ growth of 21.23% from Rs 11,112 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total income for the quarter stood at Rs 14,077 lakh, an increase of 20.11% YoY from Rs 11,720 lakh in Q1FY26 and an increase of 20.61% QoQ from Rs 11,672 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">The company reported a standalone net profit of Rs 139 lakh in Q1FY27, turning profitable YoY from a loss of Rs 670 lakh in Q1FY26 and QoQ from a loss of Rs 18 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Total comprehensive income for Q1FY27 was Rs 167 lakh, compared to a loss of Rs 668 lakh in Q1FY26 and a profit of Rs 59 lakh in Q4FY26.</li> <li _ngcontent-ng-c1940132427="">Earnings per share (Basic and Diluted) for Q1FY27 stood at Rs 0.23, as against Rs (1.09) in Q1FY26 and Rs (0.03) in Q4FY26.</li> </ul> <p><strong _ngcontent-ng-c1940132427="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Segment Performance (Consolidated):</strong> <ul> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Vaccines Segment:</strong> Segment revenue grew to Rs 13,467 lakh in Q1FY27, up 19.97% YoY from Rs 11,225 lakh in Q1FY26. The segment turned profitable with a profit before tax of Rs 747 lakh in Q1FY27 compared to a loss of Rs 425 lakh in Q1FY26.</li> <li _ngcontent-ng-c1940132427=""><strong _ngcontent-ng-c1940132427="">Formulations Segment:</strong> Segment revenue stood at Rs 6,490 lakh in Q1FY27, up 19.19% YoY from Rs 5,445 lakh in Q1FY26. The segment recorded a loss before tax of Rs 390 lakh for the quarter.</li> </ul> </li> <li _ngcontent-ng-c1940132427="">The company recognized exceptional income of Rs 274 lakh in the consolidated results for Q1FY27, relating to deferred consideration from the previous sale of domestic pharmaceutical brands.</li> <li _ngcontent-ng-c1940132427="">The Group has received higher long-term business orders for vaccines from key institutional customers, which resulted in higher revenues and profits during the current quarter.</li> <li _ngcontent-ng-c1940132427="">Surplus funds from the March 2022 sale of pharmaceutical formulation brands have been utilized to strengthen the working capital position and enhance capacities for manufacturing vaccine drug substances.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5789678/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 week 1 day ago